$836 Million is the total value of Novo Holdings A/S's 21 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 22.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INGN | INOGEN INC | $338,676,000 | +23.0% | 3,549,320 | 0.0% | 40.52% | +38.2% | |
| ANAB | ANAPTYSBIO INC | $72,592,000 | -13.8% | 3,033,504 | 0.0% | 8.69% | -3.1% | |
| XLRN | ACCELERON PHARMA INC | $47,224,000 | +14.8% | 1,553,937 | 0.0% | 5.65% | +29.0% | |
| SPNC | Buy | SPECTRANETICS CORP | $45,616,000 | +32.8% | 1,187,917 | +0.7% | 5.46% | +49.2% |
| DERM | Buy | DERMIRA INC | $44,720,000 | +75.2% | 1,534,664 | +105.1% | 5.35% | +96.9% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $39,253,000 | -41.4% | 3,244,046 | +0.6% | 4.70% | -34.1% |
| RARX | RA PHARMACEUTICALS INC | $38,071,000 | -12.0% | 2,031,562 | 0.0% | 4.56% | -1.1% | |
| FLXN | Buy | FLEXION THERAPEUTICS INC | $30,330,000 | -19.4% | 1,500,000 | +7.3% | 3.63% | -9.4% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $26,071,000 | +122.7% | 1,814,289 | +42.6% | 3.12% | +150.3% |
| New | NABRIVA THERAPEUTICS PLC | $24,382,000 | – | 2,326,544 | +100.0% | 2.92% | – | |
| OBSV | Sell | OBSEVA SA | $23,177,000 | -26.9% | 2,710,760 | -11.0% | 2.77% | -17.8% |
| MRUS | MERUS N V | $22,355,000 | -35.0% | 1,410,417 | 0.0% | 2.68% | -27.0% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $21,358,000 | -5.8% | 2,901,927 | 0.0% | 2.56% | +5.9% | |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $18,756,000 | -75.4% | 592,794 | -82.4% | 2.24% | -72.4% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $10,667,000 | -41.5% | 1,351,972 | -7.2% | 1.28% | -34.3% |
| IVTY | Buy | INVUITY INC | $9,888,000 | -5.7% | 1,363,848 | +3.4% | 1.18% | +6.0% |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $8,637,000 | – | 740,740 | +100.0% | 1.03% | – |
| WMGIZ | WRIGHT MED GROUP N Vright 03/01/2019 | $6,748,000 | -4.6% | 4,622,032 | 0.0% | 0.81% | +7.2% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $3,578,000 | -26.4% | 223,317 | 0.0% | 0.43% | -17.4% | |
| HTGM | Sell | HTG MOLECULAR DIAGNOSTICS INC | $3,273,000 | -63.1% | 1,230,399 | -3.9% | 0.39% | -58.4% |
| XENE | XENON PHARMACEUTICALS INC | $402,000 | -21.2% | 127,563 | 0.0% | 0.05% | -11.1% | |
| OPK | Exit | OPKO HEALTH INC | $0 | – | -259 | -100.0% | 0.00% | – |
| NBRV | Exit | NABRIVA THERAPEUTICS AG | $0 | – | -2,326,544 | -100.0% | -2.97% | – |
| IRTC | Exit | IRHYTHM TECHNOLOGIES INC | $0 | – | -2,024,448 | -100.0% | -8.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.